TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35879705
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine and 0.5 µg/mL sufentanil
Study: 36067452
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy with cetuximab (anti-EGFR-chemotherapy)
Study: 36067452
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy with bevacizumab (anti-VEGF-chemotherapy)
Study: 36067452
Drug: Later-line anti-EGFR-antibody
Normalized name: Anti-egfr/anti-c-met bispecific antibody emb-01
DrugBank: EMB-01 (DB16091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later-line anti-EGFR-antibody therapy
Study: 34407860
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy (specifics not provided)
Study: 33285195
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with a median dose of 33.3 Gy (range: 27 to 54 Gy) in 5 fractions
Study: 33285195
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) followed by sorafenib
Study: 32272505
Drug: Trials that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials that randomized or mandated hormone therapy
Study: 32272505
Drug: Trials that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials that did not randomize or mandate endocrine therapy
Study: 34351356
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with S-1
Study: 33032234
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy with systemic antibiotics (PT1 group)
Study: 33032234
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy without antibiotics (PT2 group)
Study: 33032234
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) with no periodontal therapy
Study: 33032234
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (PT1 and PT2)
Study: 32811843
Drug: ADV7103 (alkalising
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV7103 (alkalising agent) at doses of 1.44 meq/kg twice a day
Study: 36153625
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 4 mg/kg/h continuous infusion)
Study: 36153625
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (same volumes as lidocaine)
Study: 33599356
Drug: E6011 (anti-fractalkine
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 (anti-fractalkine antibody) 2, 5, 10, and 15 mg/kg intravenously every 2 weeks during the 12-week multiple ascending dose phase.
Study: 33289953
Drug: AGS‐16C3F 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGS‐16C3F 1.8 mg/kg every 3 weeks
Study: 33289953
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice daily (starting dose)
Study: 33922334
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with visual and oral instructor prompts to stand
Study: 35258786
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone
Study: 32954688
Drug: Sina curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sina curcumin capsules 80 mg
Study: 35464292
Drug: Intravenous dasiglucagon
Normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dasiglucagon (doses ranged from 0.03 mg to 1.5 mg)
Study: 35464292
Drug: Subcutaneous dasiglucagon
Normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous dasiglucagon (0.6 mg)
Study: 34266452
Drug: Aspirin, Atorvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, Atorvastatin, Nicorandil (Aspirin 325 mg starting dose, 75 mg once daily; Atorvastatin 40 mg starting dose, 40 mg once daily; Nicorandil 10 mg starting dose, 5 mg twice daily) plus conventional therapy
Study: 32052264
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg BID
Study: 36397132
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine, administered in three monthly rounds at the beginning of the malaria transmission season.
Study: 36397132
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine.
Study: 35605609
Drug: Pramipexole (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (dose titrated from 0.25 mg/d to 1.0 mg/d)
Study: 35750681
Drug: IBI362 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 (3.0 mg, 4.5 mg or 6.0 mg)
Study: 38508975
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol
Study: 35814305
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT) with oral drug treatment
Study: 35814305
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug treatment only (Control)
Study: 35038723
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg maintenance dose every 3 weeks
Study: 35038723
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg maintenance dose every 3 weeks
Study: 35038723
Drug: 2.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/kg maintenance dose every 3 weeks
Study: 35038723
Drug: Induction dose
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dose alone
Study: 35038723
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg maintenance dose
Study: 35038723
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg maintenance dose
Study: 35038723
Drug: 2.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/kg maintenance dose
Study: 34153943
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies with statistically significant OS endpoints (56 trials)
Study: 34153943
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies with non-significant OS endpoints (131 trials)
Study: 34153943
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies with PRS endpoints (total analyzed: 216)
Study: 35362709
Drug: Modified surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified surgical approach (Method for surgical treatment of odontogenic oral phlegmon of mouth floor with partial dissection of sublingual‐submandibular sac)
Study: 34667852
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) therapy
Study: 33325799
Drug: RT234 (vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT234 (vardenafil inhalation powder) single doses of 0.2-2.4 mg
Study: 33325799
Drug: RT234 (vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT234 (vardenafil inhalation powder) repeated doses of up to 2.4 mg q4h for four doses daily for 9 days
Study: 33325799
Drug: RT234 (vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT234 (vardenafil inhalation powder)
Study: 33325799
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vardenafil tablets (Levitra®)
Study: 34187823
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (no treatment or any other treatment of their choice)
Study: 32611865
Drug: Novel herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel herbal anesthetic gel
Study: 33783506
Drug: Intramuscular procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular procaine G penicillin
Study: 32926603
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) starting at 20 mg/d and titrated to a maximum of 70 mg/d
Study: 33513650
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy containing anticoagulation, corticosteroids, and TPE or intravenous immunoglobulin in CAPS
Study: 32513684
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect heterogeneity across baseline risk
Study: 32513684
Drug: Economic models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Economic models for RCT enrollment and treatment choice decisions
Study: 33234644
Drug: Medicines at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicines at Transitions Intervention (MaTI)
Study: 33551214
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate gel (Timoptol® LP 0.5%) applied every 2 days for 12 weeks as adjuvant therapy to standard care.
Study: 33551214
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate gel (Timoptol® LP 0.5%) applied every 2 days for 12 weeks.
Study: 32876010
Drug: Isoniazid 900
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid 900 mg given twice weekly for 12 months
Study: 34657346
Drug: Exergaming (interactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exergaming (interactive cycling at least twice a week for 6 months)
Study: 33409540
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with steroids, six food elimination diet, mesalamine
Study: 35679831
Drug: LAight® therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAight® therapy (8 sessions during period B)
Study: 35679831
Drug: LAight® therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAight® therapy (group TC + L/L)
Study: 35679831
Drug: LAight® therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAight® therapy (group TC/L)
Study: 35679831
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin 1% solution (group TC)
Study: 35679831
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin 1% solution combined with LAight® therapy (group TC + L)
Study: 35679831
Drug: LAight® therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAight® therapy (during period B)
Study: 32852967
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with higher affiliative behaviors
Study: 32852967
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with nonreciprocal relationship in dominance dimension
Study: 32852967
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with complementarity in dominance dimension
Study: 32852967
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with interpersonal problems of communion
Study: 616505213
Drug: Intraoperative injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of botulinum toxin A (BTA) in the orbicularis muscle below the lower punctum of both eyes (group B)
Study: 616505213
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment with preservative‐free tear substitutes only (group A)
Study: 35972345
Drug: CIRAS model
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRAS model based on ascites discomfort score, plasma sodium levels, and diuretic treatment.
Study: 35972345
Drug: Standard ascites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ascites classification (refractory vs. diuretic-responsive)
Study: 36440779
Drug: Prospekta, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospekta, 1 tablet twice daily
Study: 34071714
Drug: n-3 PUFA-enriched
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA-enriched hen eggs (1053 mg/day)
Study: 34743118
Drug: VYC-20L (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYC-20L (20 mg/mL hyaluronic acid gel with lidocaine) administered via cannula
Study: 34743118
Drug: Needle injection
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle injection of VYC-20L
Study: 34743118
Drug: Injection-site responses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection-site responses (ISRs)
Study: 34864943
Drug: Investigator-assigned therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-assigned therapy (IAT)
Study: 616026142
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) therapy, 3 sessions over 45 days
Study: 34652564
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER intact capsule after a 10-h fast (control condition)
Study: 34652564
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER intact capsule with a standard high-fat meal
Study: 33507809
Drug: IMRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT + C (60 Gy of intensity-modulated radiation therapy over 6 weeks with concurrent weekly cisplatin)
Study: 33507809
Drug: IMRT (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT (60 Gy intensity-modulated radiation therapy over 5 weeks)
Study: 32227643
Drug: Vilaprisan 2
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 2 mg (single oral dose)
Study: 32942085
Drug: AMO-02 (tideglusib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMO-02 (tideglusib) 400 mg
Study: 32942085
Drug: AMO-02 (tideglusib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMO-02 (tideglusib) 1000 mg
Study: 32012977
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) over the left primary motor cortex for five days, combined with patient-controlled intravenous morphine analgesia (PCA-IV).
Study: 32012977
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS stimulation, combined with patient-controlled intravenous morphine analgesia (PCA-IV).
Study: 34129958
Drug: Stochastic finite
Normalized name: TITANIUM DIOXIDE 3.25 mL in 35 mL CUTANEOUS CREAM [PHYTOGENIC INFINITE FOUNDATION SPF20 NB21]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stochastic finite element model for bone-implant interface stiffness
Study: 32336177
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with curcumin 0.75 mg/mL and blue LED (67 mW/cm2, 20.1 J/cm2)
Study: 32918272
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 8–10 mg/kg of body weight
Study: 32730930
Drug: ABGS (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABGS (250 μg rhBMP6/mL ABC)
Study: 32567103
Drug: Telephone-guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-guided imagery rehearsal therapy
Study: 33462450
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg kg‐1 every 2 weeks)
Study: 32497217
Drug: Proximal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal glucose infusion
Study: 32497217
Drug: Distal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal glucose infusion
Study: 34171822
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg b.i.d. for eight weeks
Study: 32769647
Drug: Midurethral sling
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midurethral sling and behavioral and pelvic floor muscle therapy (combined group)
Study: 34261911
Drug: Spleen aminopeptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spleen aminopeptide oral lyophilized powder (SAOLP) 4 mg qd for two cycles
Study: 34261911
Drug: Spleen aminopeptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spleen aminopeptide oral lyophilized powder (SAOLP)
Study: 33507574
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg) administered 24 to 35 weeks after the last denosumab dose
Study: 35899459
Drug: GOLDIC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOLDIC therapy
Study: 35899459
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (dexamethasone)
Study: 34479593
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (1g TXA IV)
Study: 34479593
Drug: Peri-articular Injection
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular Injection of Tranexamic Acid (1g TXA injected peri-articularly)
Study: 33225963
Drug: Varenicline (promising
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (promising AUD pharmacotherapy)
Study: 36068705
Drug: IV sulopenem
Normalized name: Sulopenem
DrugBank: Sulopenem (DB15284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sulopenem followed by oral sulopenem etzadroxil/probenecid
Study: 36068705
Drug: IV ertapenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate
Study: 33734910
Drug: Preservative-Free (PF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-Free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solution
Study: 33734910
Drug: Preservative-Containing (PC)
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-Containing (PC) brimonidine/timolol fixed-combination (BTFC) ophthalmic solution
Study: 33920626
Drug: Concurrent healthier
Normalized name: ALCOHOL 4 mL TOPICAL CLOTH [HEALTHIFY Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent healthier diet liking and healthier intake
Study: 32720870
Drug: Bevacizumab (BEV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (BEV group; either monotherapy or with lomustine)
Study: 32720870
Drug: Non-BEV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-BEV group (lomustine monotherapy)
Study: 32515412
Drug: Oral counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral counseling (OR) and the use of an application (App) for smartphones
Study: 35317705
Drug: Progressive minimal
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive minimal changes to both first and second implants over a period of nine months to achieve balanced dynamic ranges.
Study: 35317705
Drug: Changes to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes to their sequential implant only (Control group).
Study: 34043719
Drug: Brazilian propolis
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazilian propolis (5 tablets daily, 508.5 mg of propolis)
Study: 34043719
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 tablets daily)
Study: 35917763
Drug: ST+ABR (cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST+ABR (cognitive-behavioral therapy for smoking cessation and approach bias retraining)
Study: 35917763
Drug: ST+Sham (cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST+Sham (cognitive-behavioral therapy for smoking cessation and sham retraining)
Study: 33114210
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Superoxide Dismutase, Alpha Lipoic Acid, Acetyl L-Carnitine, and Vitamin B12 for 12 months
Study: 32548864
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa hydrogel (twice daily for 60 days)
Study: 32548864
Drug: Placebo hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hydrogel (twice daily for 60 days)
Study: 35240263
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WP) 20 g at breakfast + 20 g at dinner
Study: 35240263
Drug: Placebo-maltodextrin (PL)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-maltodextrin (PL) 20 g at breakfast + 20 g at dinner